JP2025506318A5 - - Google Patents
Info
- Publication number
- JP2025506318A5 JP2025506318A5 JP2023547446A JP2023547446A JP2025506318A5 JP 2025506318 A5 JP2025506318 A5 JP 2025506318A5 JP 2023547446 A JP2023547446 A JP 2023547446A JP 2023547446 A JP2023547446 A JP 2023547446A JP 2025506318 A5 JP2025506318 A5 JP 2025506318A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210132762.1 | 2022-02-14 | ||
| CN202210132762.1A CN114181310B (zh) | 2022-02-14 | 2022-02-14 | 抗tigit抗体、其药物组合物及用途 |
| PCT/CN2023/075862 WO2023151693A1 (zh) | 2022-02-14 | 2023-02-14 | 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506318A JP2025506318A (ja) | 2025-03-11 |
| JP2025506318A5 true JP2025506318A5 (OSRAM) | 2026-02-27 |
Family
ID=80607015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547446A Pending JP2025506318A (ja) | 2022-02-14 | 2023-02-14 | 抗ｔｉｇｉｔ抗体と抗ｐｄ－１－抗ｖｅｇｆａ二重特異性抗体を含有する医薬組成物及び使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250034253A1 (OSRAM) |
| EP (1) | EP4273170A4 (OSRAM) |
| JP (1) | JP2025506318A (OSRAM) |
| KR (1) | KR20240145470A (OSRAM) |
| CN (1) | CN114181310B (OSRAM) |
| AU (1) | AU2023217806A1 (OSRAM) |
| CA (1) | CA3208430A1 (OSRAM) |
| IL (1) | IL314785A (OSRAM) |
| MX (1) | MX2024009976A (OSRAM) |
| WO (1) | WO2023151693A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220062503A (ko) * | 2019-08-02 | 2022-05-17 | 씨티티큐-아케소 (상하이) 바이오메드. 테크. 컴퍼니, 리미티드 | 항-pd-1 항체 및 이의 약제학적 용도 |
| CN116059341A (zh) * | 2021-07-23 | 2023-05-05 | 中山康方生物医药有限公司 | 药物组合物及用途 |
| CA3229166A1 (en) * | 2021-08-20 | 2023-02-23 | Zhongmin Wang | Fusion protein containing anti-tigit antibody and tgf-?r, and pharmaceutical composition and use thereof |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| CN116284395B (zh) * | 2022-12-12 | 2024-11-08 | 合肥天港免疫药物有限公司 | 抗cd155的抗体及其应用 |
| CN116143923B (zh) * | 2022-12-30 | 2025-11-11 | 合肥天港免疫药物有限公司 | 高亲和力tigit抗体及其应用 |
| CN118515778A (zh) * | 2023-02-20 | 2024-08-20 | 中山康方生物医药有限公司 | 包含TGF-βRII胞外区片段的融合蛋白、其药物组合物及用途 |
| WO2025056056A1 (zh) * | 2023-09-14 | 2025-03-20 | 中山康方生物医药有限公司 | 药物组合及用途 |
| CN120530139A (zh) * | 2023-12-29 | 2025-08-22 | 成都优洛生物科技有限公司 | 抗tl1a抗体或其抗原结合片段及应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| KR101510065B1 (ko) * | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| EP4209510B1 (en) * | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| US10323095B2 (en) | 2014-03-17 | 2019-06-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| CR20170060A (es) * | 2014-08-19 | 2017-04-18 | Merck Sharp & Dohme | Anticuerpos anti tigit |
| PH12022553648A1 (en) | 2015-09-25 | 2024-03-11 | Genentech Inc | Anti-tigit antibodies and methods of use |
| RS64576B1 (sr) * | 2017-05-01 | 2023-10-31 | Agenus Inc | Anti-tigit antitela i postupci njihove primene |
| US11512129B2 (en) * | 2017-09-29 | 2022-11-29 | Jiangsu Hengrui Medicine Co., Ltd. | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN111196852A (zh) * | 2018-11-16 | 2020-05-26 | 四川科伦博泰生物医药股份有限公司 | 抗tigit抗体及其用途 |
| BR112022010069A2 (pt) * | 2019-11-25 | 2022-09-06 | Akeso Biopharma Inc | Anticorpo biespecífico, molécula de ácido nucleico isolada, vetor, célula hospedeira, conjugado, kit, uso do anticorpo biespecífico e composição farmacêutica |
| CN110960543A (zh) * | 2019-12-10 | 2020-04-07 | 安徽瀚海博兴生物技术有限公司 | 一种联合抗vegf-抗pd1双特异性抗体用于制备抗癌药物 |
| TWI813934B (zh) * | 2020-01-21 | 2023-09-01 | 大陸商甫康（上海）健康科技有限責任公司 | 一種雙特異性抗pd-l1/vegf抗體及其用途 |
| EP4096646A1 (en) * | 2020-01-27 | 2022-12-07 | Genentech, Inc. | Methods for treatment of cancer with an anti-tigit antagonist antibody |
| WO2021263085A2 (en) * | 2020-06-25 | 2021-12-30 | Arch Oncology, Inc. | Combination therapy for the treatment of solid and hematological cancers |
| EP4192883A4 (en) * | 2020-08-05 | 2024-12-04 | Crystal Bioscience Inc. | Anti-tigit antibody and methods of use thereof |
| US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
-
2022
- 2022-02-14 CN CN202210132762.1A patent/CN114181310B/zh active Active
-
2023
- 2023-02-14 EP EP23745373.3A patent/EP4273170A4/en active Pending
- 2023-02-14 US US18/264,138 patent/US20250034253A1/en active Pending
- 2023-02-14 IL IL314785A patent/IL314785A/en unknown
- 2023-02-14 KR KR1020247026551A patent/KR20240145470A/ko active Pending
- 2023-02-14 MX MX2024009976A patent/MX2024009976A/es unknown
- 2023-02-14 CA CA3208430A patent/CA3208430A1/en active Pending
- 2023-02-14 AU AU2023217806A patent/AU2023217806A1/en active Pending
- 2023-02-14 JP JP2023547446A patent/JP2025506318A/ja active Pending
- 2023-02-14 WO PCT/CN2023/075862 patent/WO2023151693A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11155615B2 (en) | Anti-ROR1 antibodies | |
| RU2016147206A (ru) | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака | |
| JP2008531576A5 (OSRAM) | ||
| JP2024520666A5 (OSRAM) | ||
| JP2024509018A5 (OSRAM) | ||
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| JP2024515618A5 (OSRAM) | ||
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| Guo et al. | A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer | |
| JP2025520232A5 (OSRAM) | ||
| US11648310B2 (en) | Combination of anti-FGFR4-antibody and bile acid sequestrant | |
| JP2024536383A5 (OSRAM) | ||
| CN101175495B (zh) | 抗癌化合物的组合 | |
| CN103768596B (zh) | 用于肿瘤治疗的组合产品、其用途及相关方法 | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| TW202214287A (zh) | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 | |
| CA3304458A1 (en) | Pharmaceutical combination and use | |
| JP7840569B2 (ja) | ヒト４－１ｂｂアゴニスト抗体およびその使用方法 | |
| RU2025127006A (ru) | Анти-lag3 антитело, фармацевтическая композиция и применение | |
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| HK40080887A (en) | Use of antibody in anti-tumor treatment | |
| CN120957726A (zh) | 抗体-药物偶联物与癌症疗法的组合及其用途 | |
| RU2025130923A (ru) | Медицинское применение анти-ctla4 и анти-pd-1 биспецифического антитела | |
| AU2024251723A1 (en) | Medical use of anti-ctla4 and anti-pd-1 bispecific antibody |